These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India. Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647 [TBL] [Abstract][Full Text] [Related]
5. Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications. Court R; Chirehwa MT; Wiesner L; Wright B; Smythe W; Kramer N; McIlleron H Int J Tuberc Lung Dis; 2018 May; 22(5):537-543. PubMed ID: 29663959 [TBL] [Abstract][Full Text] [Related]
6. Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing-Using Rifampicin as an Example. Keutzer L; Simonsson USH Front Pharmacol; 2020; 11():794. PubMed ID: 32536870 [TBL] [Abstract][Full Text] [Related]
7. Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin. Susanto BO; Svensson EM; Te Brake L; Aarnoutse RE; Boeree MJ; Simonsson USH; Int J Antimicrob Agents; 2023 Jun; 61(6):106813. PubMed ID: 37037318 [TBL] [Abstract][Full Text] [Related]
8. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868 [TBL] [Abstract][Full Text] [Related]
9. Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial. Wasserman S; Davis A; Stek C; Chirehwa M; Botha S; Daroowala R; Bremer M; Maxebengula M; Koekemoer S; Goliath R; Jackson A; Crede T; Naude J; Szymanski P; Vallie Y; Moosa MS; Wiesner L; Black J; Meintjes G; Maartens G; Wilkinson RJ Antimicrob Agents Chemother; 2021 Jul; 65(8):e0014021. PubMed ID: 33972248 [TBL] [Abstract][Full Text] [Related]
10. Optimization of a paediatric fixed dose combination mini-tablet and dosing regimen for the first line treatment of tuberculosis. Tsiligiannis A; Sfouni M; Nalda-Molina R; Dokoumetzidis A Eur J Pharm Sci; 2019 Oct; 138():105016. PubMed ID: 31356869 [TBL] [Abstract][Full Text] [Related]
11. A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines. Pinto JA; Capparelli EV; Warshaw M; Zimmer B; Cressey TR; Spector SA; Qin M; Smith B; Siberry GK; Mirochnick M; Pediatr Infect Dis J; 2018 Feb; 37(2):e29-e35. PubMed ID: 29088027 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of dosing strategy for pembrolizumab for oncology indications. Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation. Prasitsuebsai W; Cressey TR; Capparelli E; Vanprapar N; Lapphra K; Chokephaibulkit K Pediatr Infect Dis J; 2012 Apr; 31(4):389-91. PubMed ID: 22146740 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers. Medellín-Garibay SE; Milán-Segovia Rdel C; Magaña-Aquino M; Portales-Pérez DP; Romano-Moreno S J Pharm Pharmacol; 2014 Oct; 66(10):1421-8. PubMed ID: 24841364 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536 [TBL] [Abstract][Full Text] [Related]
18. Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-Native Tuberculosis Patients in Paraguay: An Exploratory Study. Ghimire S; Molinas G; Battaglia A; Martinez N; Gómez Paciello L; Aguirre S; Alffenaar JC; Sturkenboom MGG; Magis-Escurra C Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111575 [TBL] [Abstract][Full Text] [Related]
19. Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis. Mezochow A; Thakur KT; Zentner I; Subbian S; Kagan L; Vinnard C Int J Infect Dis; 2019 Jul; 84():15-21. PubMed ID: 31051278 [TBL] [Abstract][Full Text] [Related]
20. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]